Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 97

Similar articles for PubMed (Select 24078717)

1.

Dopamine agonist withdrawal syndrome (DAWS) in a patient with a microprolactinoma.

Demartini B, Ricciardi L, Ward A, Edwards MJ.

J Neurol Neurosurg Psychiatry. 2014 Apr;85(4):471. doi: 10.1136/jnnp-2013-306043. Epub 2013 Sep 27. No abstract available.

PMID:
24078717
2.

Clinical features of dopamine agonist withdrawal syndrome in a movement disorders clinic.

Pondal M, Marras C, Miyasaki J, Moro E, Armstrong MJ, Strafella AP, Shah BB, Fox S, Prashanth LK, Phielipp N, Lang AE.

J Neurol Neurosurg Psychiatry. 2013 Feb;84(2):130-5. doi: 10.1136/jnnp-2012-302684. Epub 2012 Aug 29.

PMID:
22933817
3.

Dopamine agonist withdrawal syndrome (DAWS): perils of flicking the dopamine 'switch'.

Edwards MJ.

J Neurol Neurosurg Psychiatry. 2013 Feb;84(2):120. doi: 10.1136/jnnp-2012-303570. Epub 2012 Sep 19. No abstract available.

PMID:
22993451
4.

The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas.

Di Sarno A, Landi ML, Marzullo P, Di Somma C, Pivonello R, Cerbone G, Lombardi G, Colao A.

Clin Endocrinol (Oxf). 2000 Jul;53(1):53-60.

PMID:
10931080
5.

Treating prolactinoma and psychosis: medication and cognitive behavioural therapy.

Nieman DH, Sutterland AL, Otten J, Becker HE, Drent ML, van der Gaag M, Birchwood M, de Haan L.

BMJ Case Rep. 2011 Feb 9;2011. pii: bcr0720103185. doi: 10.1136/bcr.07.2010.3185.

6.

Dopamine agonist withdrawal syndrome: implications for patient care.

Nirenberg MJ.

Drugs Aging. 2013 Aug;30(8):587-92. doi: 10.1007/s40266-013-0090-z. Review.

PMID:
23686524
7.

Dopamine agonist withdrawal syndrome in Parkinson disease.

Rabinak CA, Nirenberg MJ.

Arch Neurol. 2010 Jan;67(1):58-63. doi: 10.1001/archneurol.2009.294.

PMID:
20065130
8.

Prolactinomas and pregnancy.

Molitch ME.

Clin Endocrinol (Oxf). 2010 Aug;73(2):147-8. doi: 10.1111/j.1365-2265.2010.03823.x. Epub 2010 Jun 9. No abstract available.

PMID:
20550542
9.

[Prolactinoma and pregnancy].

Trifonov I.

Akush Ginekol (Sofiia). 2004;43 Suppl 2:16-22. Review. Bulgarian. No abstract available.

PMID:
15518268
10.

Identification of possible risk factors for the development of dopamine agonist withdrawal syndrome in Parkinson's disease.

Cunnington AL, White L, Hood K.

Parkinsonism Relat Disord. 2012 Nov;18(9):1051-2. doi: 10.1016/j.parkreldis.2012.05.012. Epub 2012 Jun 6. No abstract available.

PMID:
22677468
11.

Potential for long-term remission of microprolactinoma after withdrawal of dopamine-agonist therapy.

Bronstein MD.

Nat Clin Pract Endocrinol Metab. 2006 Mar;2(3):130-1. No abstract available.

PMID:
16932269
12.

[Treatment of macroprolactinomas with quinagolide (Norprolac)].

Tabarin A, Catargi B.

Ann Endocrinol (Paris). 1997;58(2):87-94. Review. French.

PMID:
9239226
13.

Dopamine agonist-induced impulse control disorders in a patient with prolactinoma.

Almanzar S, Zapata-Vega MI, Raya JA.

Psychosomatics. 2013 Jul-Aug;54(4):387-91. doi: 10.1016/j.psym.2012.10.002. Epub 2012 Dec 20. No abstract available.

PMID:
23261076
14.

Addiction-like manifestations and Parkinson's disease: a large single center 9-year experience.

Limotai N, Oyama G, Go C, Bernal O, Ong T, Moum SJ, Bhidayasiri R, Foote KD, Bowers D, Ward H, Okun MS.

Int J Neurosci. 2012 Mar;122(3):145-53. doi: 10.3109/00207454.2011.633722. Epub 2011 Dec 6.

PMID:
22023411
15.
16.

Recurrence of hyperprolactinaemia following discontinuation of dopamine agonist therapy in patients with prolactinoma occurs commonly especially in macroprolactinoma.

Barber TM, Kenkre J, Garnett C, Scott RV, Byrne JV, Wass JA.

Clin Endocrinol (Oxf). 2011 Dec;75(6):819-24. doi: 10.1111/j.1365-2265.2011.04136.x.

PMID:
21645021
17.

Dopamine agonist withdrawal syndrome and non-motor symptoms after Parkinson's disease surgery.

Nirenberg MJ.

Brain. 2010 Nov;133(11):e155; author reply e156. doi: 10.1093/brain/awq165. Epub 2010 Jul 21. No abstract available.

18.

Prolactin-secreting pituitary adenoma in neuroleptic treated patients with psychotic disorder.

Melkersson K, Hulting AL.

Eur Arch Psychiatry Clin Neurosci. 2000;250(1):6-10.

PMID:
10738858
19.

Prolactinoma causing secondary amenorrhea in a woman with Ullrich-Turner syndrome.

Dötsch J, Schoof E, Hensen J, Dörr HG.

Horm Res. 1999;51(5):256-7.

PMID:
10559672
20.

Headache induced by dopamine agonists prescribed for prolactinoma: think SUNCT!

Larner AJ.

Int J Clin Pract. 2006 Mar;60(3):360-1.

PMID:
16494654
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk